Ronald Davis
Dermatology · San Antonio, TXNPI 1497770572
Payments from drug & device makers
Across 118 payments — averaging $35.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$543
- Johnson & Johnson$459
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$450
- Incyte Corporation$335
- Pfizer$302
- Regeneron Healthcare Solutions, Inc.$293
- plus $2K from 20 others
What the payments were for
- Travel & lodging$100%
- Food & beverage$3,95094%
- Education$2636%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 16 | $543 |
| Johnson & Johnson | 17 | $459 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $450 |
| Incyte Corporation | 7 | $335 |
| Pfizer | 7 | $302 |
| Regeneron Healthcare Solutions, Inc. | 5 | $293 |
| Sanofi | 10 | $274 |
| UCB, Inc. | 8 | $268 |
| AbbVie | 9 | $248 |
| Amgen | 6 | $206 |
| E.r. Squibb & Sons, L.L.C. | 3 | $161 |
| Boehringer Ingelheim | 1 | $122 |
| Janssen Scientific Affairs, LLC | 1 | $108 |
| Novartis | 5 | $96 |
| Galderma Laboratories, L.p. | 2 | $91 |
| Dermavant Sciences, Inc. | 2 | $43 |
| Biofrontera Inc. | 2 | $35 |
| Organon | 2 | $30 |
| LEO Pharma Inc. | 1 | $26 |
| DUSA Pharmaceuticals, Inc. | 1 | $24 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Arcutis Biotherapeutics, Inc. | 1 | $21 |
| Dermira, Inc. | 1 | $20 |
| Alk-abello, Inc | 1 | $18 |
| Bristol Myers Squibb | 1 | $18 |
| Almirall LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,223 in reported general payments places this provider in the 45th percentile of 1,098 dermatology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $119,146 |
| OtezlaApremilast | 18 | $87,231 |
| Clobetasol Propionate | 45 | $1,494 |
| Doxycycline Hyclate | 22 | $1,492 |
| Imiquimod | 25 | $811 |
| Metronidazole | 13 | $495 |
| Hydrocortisone Valerate | 13 | $424 |
| Hydrocortisone | 29 | $275 |
| Triamcinolone Acetonide | 21 | $236 |
| Hydroxyzine Hcl | 20 | $203 |
| Ketoconazole | 14 | $121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $206 | $87,23118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,098 dermatology providers in Texas.
Other dermatology in San Antonio
- Mark LeeSan Antonio$10.9M
- John BrowningSan Antonio$10.7M
- Emily BeckerSan Antonio$2.4M
- William CragunSan Antonio$2.3M
- Steven DavisSan Antonio$1.8M
- Lindsey FinkleaSan Antonio$1.2M
- Stephen MillerSan Antonio$389K
- Vivian BucaySan Antonio$241K
- Stephen TyringWebster$14.1M
- Edward LainAustin$12M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.